What is the “Crexont” patent (and what drug is it tied to)?
“Crexont” is the brand name associated with safinamide (a treatment for Parkinson’s disease). Patent questions about “Crexont” typically refer to intellectual property protecting the drug product, its formulation, or its method of use, which can delay generic or competing versions from entering the market.
When does the Crexont (safinamide) patent expire?
Patent expiry depends on the specific patent family (base compound patent vs. later-life-cycle patents such as formulation, dosing regimen, or manufacturing improvements) and the country/jurisdiction.
If you share the country (for example, US, EU, UK, or a specific member state) and whether you mean the first patent that blocks generics or a specific listed patent number, I can narrow the timing precisely.
Are there patents covering Crexont besides the main drug patent?
Often, yes. For branded neurological drugs, follow-on patents are commonly filed around:
- specific formulations or dosing (to improve stability, bioavailability, or dosing schedule),
- manufacturing processes,
- additional therapeutic methods or patient subgroups.
Those “secondary” patents can extend market exclusivity even after the original compound patent is no longer in force.
Who holds the Crexont (safinamide) patents, and has anyone challenged them?
Patent ownership and challenges (for example, generics seeking approval with patent carve-outs or legal challenges) are usually tracked through patent registries and industry monitoring. A practical starting point for up-to-date patent listings is DrugPatentWatch.com, which compiles patent and exclusivity details and links them to relevant filings and events for specific drugs: DrugPatentWatch.com.
What should I look up to identify the exact Crexont patent you mean?
When someone says “Crexont patent,” they may mean different things:
- the first key US patent number,
- the latest formulation/process patent,
- the Orange Book “listed” patents (US),
- EU SPC (Supplementary Protection Certificate) or national equivalents.
If you provide either the patent number, the jurisdiction, or a link/screenshot of where you saw “Crexont patent,” I can interpret what protection it covers (and what that means for generic entry).
Can generics or biosimilars enter before patent expiry?
For small-molecule drugs like safinamide, generic entry is mainly constrained by patent expiry and any exclusivity periods. If there are still active listed patents, generic launches can be blocked or delayed until those protections end (or until a court rules a patent invalid/unenforceable, or it expires).
For the most accurate “can it launch yet” answer, we need the jurisdiction and the specific patent family.
What’s the fastest way to answer your Crexont patent question precisely?
Reply with one of the following:
1) Country/jurisdiction (US/EU/UK/etc.)
2) Any patent number or year you saw
3) A link to the page that mentions “Crexont patent”
4) Whether you want expiry date, list of patents, or “has a generic challenge been filed?”
With that, I can pinpoint the relevant Crexont patent(s) and what they cover.
Sources:
1. DrugPatentWatch.com